Successful treatment of Lambert‑Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4‑diaminopyridine: A case report

Hyun,Jae‑Won; Kim,Su‑Hyun; Jeong,In Hye; Kim,Heung Tae; Kim,Ho Jin

doi:10.3892/ol.2016.4123

March-2016 Volume 11 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2016 Volume 11 Issue 3

Full Size Image

Case Report

Successful treatment of Lambert‑Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4‑diaminopyridine: A case report

Authors:
- Jae‑Won Hyun
- Su‑Hyun Kim
- In Hye Jeong
- Heung Tae Kim
- Ho Jin Kim
View Affiliations / Copyright

Affiliations: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Gyeonggi 410‑769, Republic of Korea, Center for Lung Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Gyeonggi 410‑769, Republic of Korea
Pages: 1933-1935
|
Published online on: January 18, 2016

https://doi.org/10.3892/ol.2016.4123
Expand metrics +

Abstract

Lambert‑Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular junction that is characterized by muscle weakness. LEMS is usually associated with cancer, most commonly small cell lung cancer (SCLC). The potassium‑channel blocker 3,4‑diaminopyridine (3,4‑DAP), has been previously used for the symptomatic treatment of LEMS. 3,4‑DAP increases the release of acetylcholine and prolongs the duration of nerve action potentials at the presynaptic membrane of the neuromuscular junction. The present study describes the case of a patient with LEMS and SCLC, for which the symptoms did not improve with anticancer therapy, but did so markedly following treatment with 3,4‑DAP. The present study illustrates that 3,4‑DAP is a useful treatment choice in patients with LEMS, particularly for patients who do not fully improve following anticancer therapy.

View Figures

View References

1	Lambert EH and Elmqvist D: Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci. 183:183–199. 1971. View Article : Google Scholar : PubMed/NCBI
2	Titulaer MJ, Lang B and Verschuuren JJ: Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. Lancet Neurol. 10:1098–1107. 2011. View Article : Google Scholar : PubMed/NCBI
3	O'Neill JH, Murray NM and Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 111:577–596. 1988. View Article : Google Scholar : PubMed/NCBI
4	Maddison P: Treatment in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci. 1275:78–84. 2012. View Article : Google Scholar : PubMed/NCBI
5	Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA and Verschuuren JJ: Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 26:4276–4281. 2008. View Article : Google Scholar : PubMed/NCBI
6	Thomsen RH and Wilson DF: Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther. 227:260–265. 1983.PubMed/NCBI
7	McEvoy KM, Windebank AJ, Daube JR and Low PA: 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 321:1567–1571. 1989. View Article : Google Scholar : PubMed/NCBI
8	Sanders DB, Massey JM, Sanders LL and Edwards LJ: A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 54:603–607. 2000. View Article : Google Scholar : PubMed/NCBI
9	Medical Research Council: Aids to the examination of the peripheral nervous system. Memorandum No 45 (London, UK). Her majesty's stationery office. 1967.
10	Oh SJ: Repetitive Nerve Stimulation Test Principles of Clinical Electromyography: Case studies (1st). Baltimore, MD, USA: Williams & Wilkins. 59–75. 1998.
11	Lee JH, Shin HY, Kim SM and Sunwoo IN: A case of lambert-eaton myasthenic syndrome with small-cell lung cancer and transient increase in anti-acetylcholine-receptor-binding antibody titer. J Clin Neurol. 8:305–307. 2012. View Article : Google Scholar : PubMed/NCBI
12	Shin DS, Park HY and Cho KH: Marked improvement of Lambert-Eaton syndrome with the chemotherapy of small cell lung carcinoma. J Korean Neurol Assoc. 24:95–97. 2006.
13	Lee SA, Sunwoo IN, Ro JK and Park KD: A case of remitted Lambert-Eaton Myathenic syndrome with small cell lung carcinoma following chemotherapy and radiotherapy. J Korean Neurol Assoc. 8:393–400. 1990.
14	Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH and Spiro SG: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 40:1552–1556. 1990. View Article : Google Scholar : PubMed/NCBI
15	Oh SJ, Claussen GG, Hatanaka Y and Morgan MB: 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 40:795–800. 2009. View Article : Google Scholar : PubMed/NCBI
16	Uekita K, Ishida T, Sekine S, Ishii T, Sato S, Sugawara A, Tachihara M, Watanabe K, Kanazawa K, Saito J, et al: A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine. Nihon Kokyuki Gakkai Zasshi. 47:76–80. 2009.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful treatment of Lambert‑Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4‑diaminopyridine: A case report

This article is mentioned in:

Abstract

Figure 1

Related Articles